Island Pharmaceuticals reports clinical progress and expanded pipeline

Island Pharmaceuticals (ASX:ILA) has declared the financial year 2025 as defining, having delivered encouraging trial results for its dengue program and acquired a second antiviral asset, which positions the company as a dual-asset player in global infectious diseases. …